GlassScriptPhysician profile
Ruojin S Ren
NPI 1265085336
$7,547.39
in general payments reported to CMS, 2019-2025
18 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $60.29 · 2021: $541 · 2022: $1,048 · 2023: $969 · 2024: $1,434 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459 · Travel and Lodging: $820 · Entertainment: $29.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,458.71 |
| Travel and Lodging | $820.08 |
| Entertainment | $29.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,744.00 | 2024-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,341.02 | 2019 | |
| Alcon Vision LLC | $1,036.53 | 2022-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Coopervision INC. | $599.22 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Paragon Crt |
| Horizon Therapeutics Plc | $538.31 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $464.31 | 2022-2023 | Omni Surgical System |
| Allergan, INC. | $379.96 | 2019-2022 | |
| Glaukos Corporation | $318.16 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $311.80 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $147.81 | 2021-2023 | |
| Astellas Pharma US INC | $139.37 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $124.99 | 2019 | |
| Abbvie INC. | $121.46 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $116.14 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $94.35 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $29.08 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $23.67 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $17.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruojin Ren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.